Medicure (MCUJF) Stock Price, News & Analysis

Company Overview

Medicure Pharmaceutical Corp. is a specialty pharmaceutical company focused on the development, manufacturing and commercialization of therapies in the cardiovascular and critical‐care markets. The company advances its business through a combination of in-licensing, acquisitions and strategic partnerships designed to build a diversified portfolio of prescription products that address unmet medical needs.

Headquartered in Montreal, Canada, Medicure operates in North America and selectively in Europe through licensing agreements with regional distributors. Its commercial portfolio includes branded cardiovascular products, while its research and development pipeline features small‐molecule candidates targeting acute heart failure, pulmonary hypertension and related conditions. The company leverages its regulatory and clinical expertise to shepherd assets from late‐stage development through to market access.

Since its founding in 2004, Medicure has grown by forging collaborations with both larger pharmaceutical companies and specialty distributors, aiming to accelerate product launches and maximize reach in key therapeutic segments. The senior leadership team brings decades of experience in drug development, regulatory affairs and commercial operations, positioning Medicure to advance its niche cardiovascular and critical‐care medicines to patients in need.

Key Stats

• Today's Range: $0.96 to $0.96
• 50-Day Range: $0.67 to $0.96
• 52-Week Range: $0.67 to $0.97
• Volume: 10,000 shs
• Average Volume: 1,480 shs
• Market Capitalization: $10.06 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Medicure Stock Analysis - MarketRank™

Medicure scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Medicure.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Medicure is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Medicure is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Medicure has a P/B Ratio of 1.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Medicure has been sold short.

Short Interest Ratio / Days to Cover

Medicure has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Medicure has recently decreased by 99.88%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Medicure does not currently pay a dividend.

Dividend Growth

Medicure does not have a long track record of dividend growth.

News and Social Media

• Score: 0.3 / 5
• News Sentiment: N/A

News Sentiment

Medicure has a news sentiment score of -1.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Medicure this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Medicure insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.90% of the stock of Medicure is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Medicure has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 8/20/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:MCUJF
• CIK: 1133519
• Web: www.medicure.com
• Phone: (204) 487-7412
• Fax: 204-488-9823
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.51)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$5.08 million
• Net Margins: -23.14%
• Pretax Margin: -21.01%
• Return on Equity: -51.93%
• Return on Assets: -29.67%

Debt

• Debt-to-Equity Ratio: 0.03
• Current Ratio: 1.04
• Quick Ratio: 0.73

Sales & Book Value

• Annual Sales: $20.65 million
• Price / Sales: 0.49
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.89 per share
• Price / Book: 1.08

Miscellaneous

• Outstanding Shares: 10,440,000
• Free Float: 9,090,000
• Market Cap: $10.06 million
• Optionable: Not Optionable
• Beta: 0.99